Allergan profit falls as Botox sales slump

By Staff Writers
Thursday, 28 April, 2005

Drugmaker Allergan said quarterly net earnings fell slightly, and sales of Botox missed analyst forecasts, sending shares down 2 per cent.

First-quarter profit was US$79.9 million, or 60 cents per share, compared with $80.8 million or 60 cents per share a year earlier.

Net sales rose to $527 million, from $472 million in the year earlier period.

Botox sales were $176 million, about $10 million short of analyst views.

The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...

To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...

Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...

Content from other channels on our network

Renewables supply reaches almost 50% on Aust's east coast

Quantum timing study to help future-proof energy grid

New method to extract microplastics from soil: study

Water treatment plant receives 'Blue Loan'

Australians need to take care when recycling

Belden demonstrates 5G industrial switch

Federal government invests in solid rocket motor manufacturing

Measurement Solutions joins the Bestech Group: a significant step into the process industries

Supply chain dependencies pose risks to renewable energy goals: study

Building grid resilience with quantum timing

A Day in the Life of a hospital's injury management team manager

Stabbing of on-duty paramedic leads to attempted murder charge

Major works complete on $45.36m Snowy River Views Residential Care

Clinical environments are changing. Healthcare solutions must change with them.

Improving care for some of the sickest patients in the hospital: new national standard for emergency laparotomy